ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Novavax Inc

Novavax Inc (NVAX)

14.42
-0.26
(-1.77%)
Closed October 03 3:00PM
14.37
-0.05
( -0.35% )
Pre Market: 3:43AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

NVAX News

Official News Only

NVAX Discussion

View Posts
EternalPatience EternalPatience 21 hours ago
Analysts upgrade and downgrade it all the time. So I believe that is something else brewing for this 20% raise yesterday. I cannot comprehend it just to be because one analyst said it's worth $31 .  100% confident about it
👍️ 1
JoeForkeyBolo JoeForkeyBolo 21 hours ago
Novavax Stock Gains Retail Spotlight After Jefferies’ Bullish Call, Firm’s Subsequent Clarification: Retail Turns Exuberant

Bhavik Nair·Stocktwits
Published Oct 3, 2024

The brokerage reportedly indicated that it caught up with Novavax management and believes that for the near term, the firm is in "a good position" to meet its 2024 revenue guidance.

Novavax Inc (NVAX) stock became the second most trending ticker on Stocktwits on Thursday morning after Jefferies gave a β€˜Buy’ rating to the stock with a price target of $31. The target represents a potential upside of over 100% from the stock’s current level.

The brokerage reportedly indicated that it caught up with Novavax management and believes that for the near term, the firm is in "a good position" to meet its 2024 revenue guidance, driven by the U.S. market. Jefferies also reportedly said that according to the company, a majority of the 24/25 COVID-19 season sales will be in Q4.

β€œFor the long term, the company is transitioning to an R&D model, with Phase 3 flu +/- CV19 as the lead that could trigger a major partnership in 2025 and new non-seasonal vaccines based on unique adjuvant technology as an earlier pipeline that would drive significant future growth,” Jefferies reportedly said.

Following the update, shares of Novavax had closed over 19% higher on Wednesday. However, Novavax came out with a clarification in an SEC filing.

The firm stated that it is aware of an analyst report published on Oct. 1, 2024, which referred to discussions with Novavax’s management regarding the anticipated U.S. market for COVID-19 vaccination for the 2024-2025 vaccination season.

β€œNovavax would like to clarify that while it has anticipated the COVID-19 vaccination market in the U.S. will be similar to last year, it has neither updated nor reaffirmed its full year 2024 financial guidance issued on August 8, 2024,” it clarified.

Shares of Novavax were trading over 5% lower in Thursday’s pre-market session. However, retail investors on Stocktwits turned β€˜extremely bullish’ (80/100) from β€˜bearish’ a day ago.

Notably, Novavax shares are up over 191% since the beginning of the year, significantly outperforming the benchmark indices. Stocktwits users with a β€˜bullish’ outlook believe the shares are likely to rally in the coming times.
https://stocktwits.com/news-articles/markets/equity/novavax-stock-in-focus-after-bullish-takes-from-jefferies/cJccSbkR3r
👍️ 1
JoeForkeyBolo JoeForkeyBolo 22 hours ago
Novavax Form 8-K filed 10/3/24

Form 8-K
Novavax, Inc. (β€œNovavax”) is aware of an analyst report published on October 1, 2024, which referred to discussions with Novavax’s management regarding, among other things, the anticipated U.S. market for COVID-19 vaccination for the 2024-2025 vaccination season. Novavax would like to clarify that while it has anticipated the COVID-19 vaccination market in the U.S. will be similar to last year, it has neither updated nor reaffirmed its full year 2024 financial guidance issued on August 8, 2024.
πŸ‘οΈ0
MarauderVoyager38 MarauderVoyager38 2 days ago
Yes. And with this paper we have a plausible mechanism why this may happen with mRNA vaccines. We would need the same data from Novavax to confirm that it does happen with it and that it creates the various memory cells in bone marrow that are typical of other protein-based vaccines. But it likely does this, as its protection is longer lasting.
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 2 days ago
I believe this issue is specific to mRNA Covid vaccines. It has been shown in testing that immunity wanes significantly after as little as 3 months, while the Novavac Covid vaccine immunity remains high for 8 months or more after vaccination.
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 2 days ago
Jeffries Reiterates Buy Rating on Novavax, Target Price $31.00

👍️ 1
MarauderVoyager38 MarauderVoyager38 2 days ago
Check out the new Nature paper that shows mRNA vaccines don't produce immune memory cells in bone marrow. Didn't know this until now. Another knock against mRNA it would seem...and this appears significant. Unknown if same holds for Novavax...but unlikely given its platform type.

"SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination."

https://www.nature.com/articles/s41591-024-03278-y
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 3 days ago
The NIH Clinical Trials database currently shows the following trials where Novavax Matrix-M adjuvant is used. Link provided to this search in case anyone wants to dig deeper in the trials listed.

28 trials – not yet recruiting
69 trials – recruiting
25 trials – active, not recruiting

https://clinicaltrials.gov/search?term=%22Matrix-M%22&limit=100&aggFilters=status:act%20rec%20not

I'm very excited to be a Novavax shareholder.
👍️ 1
LUCKYBUTT LUCKYBUTT 3 days ago
COVID IS OVER. Stock with the scare tactics
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 3 days ago
I've been continuing to trade on dips created by the short-sellers. As of this morning, have added a total of 1,883 free shares and lowered cost basis from $5.65 to $5.12/share. My goal is to roll profits back into repurchase of more shares, which I'm holding until the eventual buyout that I expect within 1 - 3 years.

This trading opportunity won't last much longer, IMO. Shorts are going to get burned badly on news of another partner, public announcement of Sanofi's plans for Matrix-M adjuvant, EMA approval of the Covid vaccine, and update on new Novavax pipeline.

While frustrating for now, the short-sellers will eventually move on to easier targets than NVAX.
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 4 days ago
Novavax's new COVID-19 vaccine gets emergency use approval in South Korea

https://en.topdaily.kr/articles/2817
👍 1
LUCKYBUTT LUCKYBUTT 4 days ago
Myocarditis is inflammation of the heart muscle, called the myocardium. The condition can reduce the heart's ability to pump blood. Myocarditis can cause chest pain, shortness of breath, and rapid or irregular heartbeats. Get another jab lol. Guess you're a big Taylor Swift fan too. LMAO
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 4 days ago
CNET – Move Over, mRNA: What to Know About the Novavax COVID Vaccine

https://www.cnet.com/health/medical/move-over-mrna-what-to-know-about-the-novavax-covid-vaccine/
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 4 days ago
I'll be sure to let Sanofi know they made a huge mistake in partnering and investing $1.3B in Novavax. I'm sorry they failed to consult you for your thoughts as part of their due diligence. Most likely they elected to ignore those who have no knowledge about Novavax, their current and forthcoming product lines, and the value of their Matrix-M adjuvant to other pharma companies.

But thanks for the entertainment.



Currently have over $146K in profit here. I'm buying more NVAX shares this week.
πŸ‘οΈ0
LUCKYBUTT LUCKYBUTT 4 days ago
covid is over. Good luck catching MONEY POX with these vax. Stop the P&D's please. This is a P&D stock
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 5 days ago
Here's an interesting data point on Novavax vaccine posted on Yahoo and Stocktwits NVAX forums.
I just spoke at Costco with 2 pharmacists, they said out of all people getting vaccinated, over 50% chose NVAX.
And less than 50% getting Pfizer and Moderna. I was at Costco at 973 3rd Avenue, Brooklyn, NY.
Go there or call to confirm, if don’t believe me. NVAX 🚀 🚀 🚀
I've also read numerous messages from investors trying to locate in-stock Novavax vaccines, where pharmacies are reporting they are already sold out of their initial shipments and are awaiting resupply. Our vaccine seems to be in high demand among those choosing to get vaccinated. 👍️

But, sadly, I've also read numerous messages where the pharmacies had never heard of Novavax and were unaware they had it in stock until the customer asked them to check. For some who knew of Novavax, they didn't understand the difference between Novavax and mRNA vaccines.
👍 1 🚀 1
JoeForkeyBolo JoeForkeyBolo 6 days ago
THE TURNAROUND MAN – John Jacobs is reshaping Novavax for the post-pandemic era



https://www.bizjournals.com/washington/news/2024/09/26/novavax-john-jacobs-vaccines-covid-flu.html

Access to the article at the link above requires a subscription.

Use this link to download the PDF of the article – 6 pages in length
PDF Link

Use this link to download the MP3 audio of the article – 13 minutes in length
MP3 Link
👍 2
JoeForkeyBolo JoeForkeyBolo 1 week ago
You should look up the definition of P&D as you are clearly uninformed. If you need someone to teach you how to use Google, let us know. Or perhaps you can use that new search engine being pumped over on the MONI site. I hope you haven't bought into that garbage. Those guys haven't made any real progress in the past and MONI is just another means to continue lining their pockets with investor money, IMO.

Did you see where I sold part of my NVAX holdings on the latest news and bought back $1.50 lower and gained $9,425 worth of FREE Novavax shares? Lowered my average cost basis from $5.63/share to $5.41 in the process. That's what some claim to be doing on the MONI board. So how are their actions not a P&D but mine are?

Novavax has a short-seller problem. The overall percentage of shares shorted has been heading lower for months, currently around 20-22% of outstanding shares. I don't short stocks and I don't buy on margin. Myself and some other NVAX investors are trying to take advantage of shorting presence by trading a little on the price swings created by these shorts. That's not illegal, and it's not pumping and dumping as you seem to believe. My outlook on Novavax has always been positive, and my outlook doesn't change on a dime like it does with most P&D'ers. Look to your own MONI board for examples.

Educate yourself more and you won't appear uninformed or ignorant in what you post. I'm guessing you don't really care. 🤣
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 1 week ago
For those investors who are unhappy with CEO Jacobs and particularly his lack of publicly addressing short sellers, travel back in time to this June 2023 podcast interview with Jacobs. Interview starts at 16:15 and is worth a listen.

Remember this was 10 months prior to the Sanofi deal and while the "going concern" statement in the filings was a major issue with the company. I think it helps put things in perspective a year later. More great things ahead for Novavax, in my opinion. I'm happy to be invested here.

πŸ‘οΈ0
LUCKYBUTT LUCKYBUTT 1 week ago
HERE IS WHERE JOEFUNKY RUNS ANOTHER P&D
😓 1
JoeForkeyBolo JoeForkeyBolo 1 week ago
I completed swing trades of NVAX in my 4 Fidelity accounts and picked up 754 free shares today. I added 37 free shares last Friday on much smaller trades. The free shares has lowered my average cost per share from $5.65 to $5.41. I've grown tired of the short-sellers killing the share price with any decent run-up so I decided to try to take advantage. I don't think this opportunity will last much longer with the news expected in the coming weeks and months. Shorts will eventually move on.
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 1 week ago
NEWS: Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

https://ir.novavax.com/press-releases/2024-09-25-Novavax-Names-Dr-Ruxandra-Draghia-Akli-as-New-Executive-Vice-President-and-Head-of-Research-Development
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 1 week ago
I've seen a lot of buyout numbers posted on other sites. I believe $50 is too low, although it seems like a good price compared to current share price. However, the new business model for creating great technology and licensing it to BP partners is just getting started. According to CEO Jacobs and other company execs speaking on numerous conference calls or presentations, they plan on licensing the Matrix-M adjuvant to others and stated there is significant interest. That tells me other partnerships are likely forthcoming, similar to the Sanofi deal.

In determining a fair buyout price that would be accepted, they would need to factor in not only the expected revenues from the Sanofi partnership, but the revenues other partners might bring over the next 5-10 years, adjusted for current valuation. My gut tells me that is far above $50/share and $100+ is more likely. While many shareholders might be willing to accept a $50 offer, I don't think the company would settle for such a low value with the revenue the new business model and the company IP would be expected to bring in the coming years.

My hope for Novavax is they partner with several BP's and when the time comes for a buyout offer, a bidding war ensues. 😎
👍️ 1
EternalPatience EternalPatience 1 week ago
What are the odds of sanofi buying them out for a healthy premium, say 50$?that would cause a short squeeze of epic proportions
πŸ‘οΈ0
EternalPatience EternalPatience 1 week ago
Patiently waiting

Eternally waiting

Eternally patient

πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 1 week ago
On the hunt for Novavax: Why people are seeking out the 'traditional' COVID vaccine

https://www.yahoo.com/lifestyle/on-the-hunt-for-novavax-why-people-are-seeking-out-the-traditional-covid-vaccine-192105984.html
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 1 week ago
Sanofi CEO believes company poised for growth from new drugs

https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-ceo-still-considering-how-split-consumer-biz-hopes-keep-stake-2024-09-23/

I feel confident the licensing of the Matrix-M adjuvant from Novavax has a lot to do with this expected growth. 😎
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 2 weeks ago
Health Canada approves Novavax's updated COVID-19 vaccine for fall

https://www.cbc.ca/news/health/novavax-covid-vaccine-2024-2025-1.7328401
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 2 weeks ago
I received the updated 2024-25 Novavax Covid vaccine this week at CVS. Other than minor soreness at the injection site and minor fatigue the next day, no side other effects to report. I received the Covid vaccine in one arm and the quadrivalent flu vaccine in the other arm, so the combined vaccines and not getting a full night's sleep the previous night probably contributed. I just slept a lot the following day recovered fine.

The pharmacy tech knew little about the non-mRNA Novavax vaccine, so I spent the time educating her a bit. The information peaked her interest and she stated she was going to research the vaccine more.

I'm looking forward to success of Novavax's Combined Influenza-Covid (CIC) vaccine and plan to get it every year once it completes testing and approval process. Matrix-M adjuvant will help it to succeed where others have failed.
👍️ 1
JoeForkeyBolo JoeForkeyBolo 2 weeks ago
Advice from the Masters that will benefit Novavax investors.







πŸ‘οΈ0
EternalPatience EternalPatience 2 weeks ago
Fantastic. Thanks for the detailed reply
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 2 weeks ago
I don't make price predictions. I do expect by end of 2024 the share price will be significantly higher than today, based on the updates management stated they will provide regarding new pipeline and strategy.

The major reason I invested in Novavax was the new CEO and his plan to change the business model. Sanofi involvement is huge and validates not only the new business model but their superior Matrix-M and Covid vaccine technologies. I expect other BP to partner in similar fashion, possibly another one added by end of 2024.

So with the new business model focused on their excellent R&D and creating new products that will be highly sought after by BP, I expect only two scenarios... both of which should greatly benefit investors.

1. Business model continues with new BP partnerships inked, resulting in billions in annual revenue growth over next several years.

2. Sanofi or one of the BP partners (or BP who hasn't partnered yet) will make offer to buy Novavax. Hopefully this creates bidding war over fear new owner won't license the Novavax technology acquired.

That's how I believe things will shape up and why I'm invested here. Sure, the short-term swings are frustrating, but I'm keeping my eye on the long goal and continuing to accumulate shares. I may start trading a portion of my holdings on any news as long as shorts continue to play their games as a means of picking up free shares.

I will state my expectations for either of these scenarios playing out is north of $100 per share, and I believe that is conservative. My cost basis is $5.65 with 93.5% of my shares purchased pre-Sanofi. GLTY
πŸ‘οΈ0
EternalPatience EternalPatience 2 weeks ago
What are your price predictions for end of 24, mid 2255 and mid 2026

πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 2 weeks ago
I don't think it will be stuck in this range forever. News coming in the fall should push it out of this range, and certainly the Covid-Influenza Combination vaccine trial results expected mid-2025 will move it higher, as they are expected to be excellent. Short interest has dropped and one of the largest shorters (State Street) has closed their short position. Those who continue to short this stock after the Sanofi deal are risking heavy losses, as more partnerships are expected and management has stated they are working towards that goal.

I have a sizable pre-Sanofi position and continue to accumulate shares at these prices.
πŸ‘οΈ0
EternalPatience EternalPatience 2 weeks ago
Stock price is stuck in low teens for ever though
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 2 weeks ago
Why Novavax is Gaining Ground in COVID-19 Vaccine Race

https://finance.yahoo.com/news/why-novavax-gaining-ground-covid-220000070.html
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 3 weeks ago
WARNING: Based on customer feedback on multiple message boards, numerous CVS locations have attempted to use the mRNA vaccine instead of the Novavax vaccine requested. Be sure to check the syringe to ensure it is the Novavax product. CVS has claimed it is a glitch in their computer system, but there have been walk-ins reported that were never in their appointment system and they still tried to administer the mRNA vaccine. It seems CVS is biased toward the mRNA vaccines and will only administer Novavax if requested (and sometimes not even then). The number of reported incidents leads me to think this is intentional. I won't be using CVS for this reason.

Be vigilant to ensure you're getting the vaccine you requested. Check the syringe. Novavax uses prefilled syringes for the 2024-2025 vaccine. This advice applies to any vaccine provider, not just CVS.

πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 3 weeks ago
Added more NVAX shares on the dip. Getting my Novavax Covid vaccine this week.
πŸ‘οΈ0
Fiberman Fiberman 3 weeks ago
Finally, just made my appointment to get the updated Novavax COVID vaccine tomorrow at CVS.
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 3 weeks ago
NEWS: Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S.

https://ir.novavax.com/press-releases/2024-09-13-Novavax-2024-2025-Formula-COVID-19-Vaccine-Available-at-Major-Pharmacies-Across-the-U-S
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 3 weeks ago
Novavax, Inc. (NVAX) H.C. Wainwright 26th Annual Global Investment Conference (Transcript)

Source: https://seekingalpha.com/article/4720037-novavax-inc-nvax-h-c-wainwright-26th-annual-global-investment-conference-transcript

Novavax, Inc. (NASDAQ:NVAX) H.C. Wainwright 26th Annual Global Investment Conference September 9, 2024 3:30 PM ET

Company Participants
Jim Kelly - CFO
Bob Walker - Head of R&D

Conference Call Participants
Vernon Bernardino - H.C. Wainwright

Vernon Bernardino

Okay. Good afternoon, everybody. Welcome to the 26th Annual H.C. Wainwright Global Investment Conference. Our next company presenting are -- that we're having a chat today is Novavax, company that by now, hopefully, all of you know really well. They have Nuvaxovid, which is one of three COVID vaccines that is in authorization or license for commercialization. One thing that I do want to highlight though is Nuvaxovid is the only protein-based vaccine that's in commercialization. The others are mRNA-based. With that, I think to begin, you mentioned in your fourth quarter annual results call that you have four drivers of the stock that you're focused on in the long term and then you also have near term drivers. Could you walk us through those four drivers and then what should we expect near term?

Jim Kelly

Absolutely. And I should first really thank you for having us again this year, Vernon here. I really appreciate you here having us here. And we've had just great meetings with investors who, given the time of year, the respiratory season and just of course, getting our COVID vaccine approved just at the end of August, so much interest. And so it's been great to be out with you. I'm joined by Bob Walker, Head of R&D. Jim Kelly, CFO. And you're exactly right. Four pillars to drive value, shareholder value for our company and especially in light of a transformative transaction, which was the Sanofi transaction we announced back in May, which is pillar number one, billions and billions of potential cash flow from that transaction. And most importantly, what they can do to take our technology and bring important vaccines to patients. So pillar number one, the Sanofi agreement. Pillar number two, our late stage pipeline. We have our own proprietary flu and a combination flu COVID vaccine that are going to read out mid next year. So that's the second pillar. Number three, is doing incremental business development deals with our Matrix platform. Again, so much value that can be created to either improve existing vaccines or create new. And then finally development of our own organic portfolio and much more on that later this year. We got a validated platform plan to do much more and we plan to do so with a lean operating platform as we continue to drive down costs, as we transition from being a commercial stage global company to one that is focused on R&D and developing value that way.

Question-and-Answer Session

Q - Vernon Bernardino

Yes. And you've been -- this is an initiative that was taken on by John Jacobs, who came on Board the beginning of last year.

Jim Kelly

That's right.

Vernon Bernardino

And so they're showing execution, which I think hasn't been totally appreciated. So let's focus briefly on the Sanofi deal. Can you tell us a little bit about the terms and opportunities it represents for you?

Jim Kelly

Well, certainly. And just in a moment before I hit that, I’d tell you what there couldn't have been more change in the last 20 odd months since John joined. I mean, I think you know it. He came in in January of 2023. And almost instantly, on that sort of end of February, early March call, mapped out strategic initiatives to transform the company. And we kind of sit here today well down that path and with humility, you're never all the way there but we're really pleased with the progress of the last you know 20 months. And one of the hallmarks, I think, of this change has been this transaction, which I'm happy to walk through in a lot more detail now. The Sanofi agreement that we announced back in May has multiple dimensions and that's why it takes a little more time to kind of be understood, inclusive of initial upfronts and milestones of the transaction itself. So $500 million upfront, a $70 million equity investment. And then you look at how milestones royalties are available to the company for both the COVID vaccine and Sanofi's ability to develop combination vaccines alongside our COVID. $700 million in milestones across both and then significant royalties across both those programs available to us. Then the fourth piece or another piece of significant value creation is Sanofi has value to our or access to our Matrix. So they can take our Matrix and apply it to their existing vaccines, all except their flu or develop new vaccines. And we've got the ability to receive up to $210 million in milestones per vaccine and receive royalties on vaccines where they put it together with our Matrix. So those royalties can go 20 years. So significant value creation across this transaction. But importantly, it was done with a market leader in respiratory vaccines. We couldn't have really chosen or scripted a better partner. And so we're thrilled with not just the terms but also who we're working with.

Vernon Bernardino

For those who don't know, I mean, Sanofi is obviously big in the vaccine space. You've probably seen commercials already by now that they market the seasonal flu vaccine Flublok and Fluzone. And so this is a company that you would want to partner with as far as the vaccine space is concerned. Because in their past, they've also acquired vaccine technology, Chiron. That's dating myself here. But you know I've known the company since 2004, so there's quite a bit of Wall Street here, my second career.

Jim Kelly

Well -- and of particular importance to us is that when you look at their portfolios of where they play in respiratory vaccines, they've got the highly innovative, highly differentiated programs that really match up well to how we develop vaccines. And so in particular, we look at the 65 plus group and just that tends to be the premium markets and the types of markets where we play. So that part worked as well.

Vernon Bernardino

Yes. And the 65 plus group is the one who usually generate the weakest immune responses to vaccines. So big pharma partners present there is going to be very advantageous and synergistic. One thing that I think is really not appreciated adequately is Matrix-M. Matrix-M is an adjuvant. Matrix-M is also a technology, as Jim said. Can you very briefly, I mean, a lot of people do know what an adjuvant is tell the audience what an adjuvant is and the various uses that perhaps Matrix-M could be expanded and adapted to?

Bob Walker

Sure. So Matrix-M is a saponin based adjuvant. Some people are familiar with the GSK product, ASO-1, also saponin based, which is an extract of a Chilean tree, of bark of a tree that grows in Chile. So it's an extract that is then combined with cholesterol and phospholipids and forms a substance that when administered along with, in our case, a nanoprotein antigen, boosts the immune response. And the type of boosting of the immune response that Matrix-M delivers is both on the humoral side. So the magnitude and the breadth of the antibody responses but also the T-cell responses, which we think gives Matrix an edge, and is one of the distinguishing factors that we see both with our COVID vaccine as well as our flu vaccine. Now we have looked at Matrix with other competing flu vaccine products that are currently not adjuvanted and produced in egg systems, and we see the same types of responses. So we think that we can potentially partner with other flu vaccine manufacturers if they're looking for an adjuvant or looking to, for example, induce a T-cell response, this might be a good adjuvant to think about. We've also looked at the ability for Matrix to boost non-viral antigens and specifically pneumococcal antigens. So pneumococcal vaccines are based on polysaccharides. Polysaccharides historically have been difficult to be immunogenic in the populations that need them the most, tend to be the extremes, the babies and the elderly. And when we combined a market leading pneumococcal vaccine with our Matrix in laboratory animals, we see the same kind of adjuvanticity.

So we think that Matrix-M has potential to boost other existing marketed vaccines. It has the ability potentially to to revisit certain antigens that have -- or certain infectious diseases where that have not been considered to be necessarily amenable to vaccines but potentially by revisiting the approach and combining with Matrix, you'll see a different -- different properties. And then I think there's the world beyond infectious diseases, which we're currently assessing. And I think that later towards the end of the year when we unveil what our new pipeline will look like and where we'll be going, I think that there will probably be some opportunities to look outside strictly infectious disease vaccines.

Vernon Bernardino

Now, what many investors may not know is those old protein vaccines that you used to take or still take that are protein based, often had an adjuvant in them called alum, which is a different or formulation of aluminum. So the idea is not new but Matrix-M is. And the basic idea is it boosts the immune response. But with Matrix-M, you perhaps have at least a 2x or many fold boost in that response. I think that's perhaps, let's see, by year end when you have the portfolio reveal how those opportunities are actually going to be best communicated and hopefully further appreciated.

Jim Kelly

Yes, I mean, you just reminded me. One of the other aspects is that the, what's called antigen-sparing property of adjuvant. So you can actually -- and that translates into better cost of goods, right? That's the point I was driving at. So if you can find the right adjuvant, you can actually lower your protein production costs, which is really where a lot of the money gets spent in manufacturing of vaccines. And so even -- you know anyway, there's other opportunities there to help folks -- other partners, for example, reduce cost of goods by looking at Matrix.

Vernon Bernardino

And the protein sparing also sort of has a little bit of quality of life aspect to it. Because can you imagine to get more immunogenicity you can also just inject more protein to get a higher response. But because of formulations that can actually be painful. And you know over time people may not get their vaccines or you know hesitate to finish a course, because it's just an injection is painful. So you imagine if you had a volume like I've had for a rabies when I got bit by a dog, you have this course of vaccines and those are huge volume injections. And so dose sparing is another aspect of the adjuvant technology you have that's underappreciated. Real quick on to CIC, which is the combination COVID seasonal influenza vaccine, positive Phase 2 results. Could you tell us a little bit about those plans and you know whether you're on track for the Phase 3 immunogenicity trials?

Jim Kelly

I'll take that one too. So yes, we're initiating a Phase 3 immunogenicity study, looking at both CIC and our standalone flu in the same Phase 3a study. And we're on track to start that in October of this year. And we're expecting our first data readout to be by mid 2025, and that's going to be a really important data readout for us, right? Because you know that's where going to see, it's gonna be very binary, we think. You know we either see non-inferiority to the market leader or we don't. And we're fully expecting that based on the Phase 2 data we are gonna see non-inferiority or not superiority, that's right. And that's going to, I think, open up the door to partnering discussions where we actually have an asset at that point that's been proven.

Jim Kelly

Really important because we're planning on investing up through these data readouts mid next year partnering and then we're seeking to have the partner advance the filing, run the Phase 3b, post marketing commitments and commercialize. And through that partnership have available upfronts, milestones and royalties as a part of continuing to monetize and create value from our pipeline.

Vernon Bernardino

Perfect. Now, as you remember that Jim mentioned earlier, one of the pillars that CEO, John Jacobs, had the company implement was getting costs under control, but yet it's a drug a, you know, a vaccine development company. So there's going to need to be spend. The results so far have been great. I think my model does expect you to at least be operationally breakeven sometime next year. I forget which quarter it is. But can you talk a little bit about those initiatives, efforts and the results you have so far?

Jim Kelly

Well, certainly. As folks heard when we started today, hey, we're a pandemic company and so we scaled up for this global reach to be able to deliver billion of doses. Well, we transitioned the company in the past few years to a post pandemic model, really cleaned up our balance sheet, cleaned up our OpEx and now are increasingly emphasizing our R&D roots. So what does that mean mathematically? Well, in 2022, we had $1.7 billion in R&D and SG&A. By 2026, we expect to have less than 350%, a 80% reduction. How the heck do you do that? Well, a lot of it is, hey, we worked our way through those operation warp speed studies. It was great, the government helped us, it was such a great help in investing in our COVID platform. Then as we move through this year and the next, this year is our last commercial year. So those roll offs, the big COVID studies roll off, the commercial front end investment rolls off next year or this year's R&D and SG&A, we expect $750 million, next year below $500 million, the year after below $350 million. So what we're able to do, the other side of this agreement with Sanofi in completing our commercialization efforts, is really resize and reshape the company to get to a more lean, agile operating model where we can operate within the parameters of the cash flows coming to us through the Sanofi agreement. We're planning to partner in new cash flows off of flu and CIC. And then you just heard from Bob, the opportunities to partner are Matrix. And we think there are vast opportunities there, both for improving existing vaccines on the market or helping develop new ones.

Vernon Bernardino

Yes, I think this is an important aspect of the investment thesis, because one of the things the company -- in this implementation is to perhaps an evolution to a commercial stage company, at some point, you want the company to be profitable, right? You can't just be spending on R&D all the time, and it's a biotech company, so you're going to plow profits into the pipeline. So there's always going to be some spend. But on the return of that investment, I think, company starts to become really attractive. And I think the homework starts now if it already hasn't been done that if the story starts to become operational breakeven that for those investors who focused on the cash flow aspect of the story, it is probably a good time to do so, because I think and my model only actually has the company capturing 10% of the COVID market, I think it's slightly higher because I think the combination vaccine -- slightly higher for the combination vaccine, because the combination vaccine, I think, will be superior to the competition that the company doesn't really necessarily need to cut that more price that high, capture that much more market share to get to what I believe is currently, right now, an attractive valuation and a price target horizon for those who don't necessarily want to hold the stock long term, which I do recommend. Real quick since we only have about a minute left in time, could you talk a little bit your cash position and perhaps how you might deploy those limited resources into clinical stage activities?

Jim Kelly

Yes, certainly. And important to emphasize, hey, it's our intent to be a profitable company. Like there should be no question about it. I'm not guiding just yet. On hey, you're saying, hey, what quarter? Hey, not guiding just yet. Hey, we're going to -- that's our goal. Our goal and our intent is to be a profitable company where we've been able to do those types of licensing arrangements that bring cash flows into the company that fully support our development efforts. And those efforts we can't wait to unveil as a part of our R&D Day later this year. Important activities that are ongoing include flu CIC that we'll read out by midyear. We've also said that we've initiated IND enabling work around both our RSV and H5N1 programs. You know those are also seeking to become partner ready. And then as we unveil these new pipeline prioritization projects that's where the funding's going to go. So much more on that front as we move forward in the coming months. Can't wait to share more.

Vernon Bernardino

So let's take a little liberty of just one more minute. Can you tell us a little bit about the steps you took and the status of the current launch for Nuvaxovid?

Jim Kelly

By the way, thank you for getting there. Just how quickly we move on to the next one. Hey, the authorization, the EUA that we received from the United States on August 30th, we couldn't be more pleased. They were -- have been such great partners with us. We did so in the summer. We're four or five weeks ahead of where we were last year. We're right here at the beginning of the season in the US, shipped to retail pharmacy late last week, expecting the ability of shots and arms this week, pre-filled syringe, really good contracting work, a lot of credit to our team, retail contracting this year to get us in pharmacies and availability across the country. So we're there. We're there now.

Vernon Bernardino

Terrific. On a personal note, I got my COVID vaccine one week before theirs was available last year. This time, it's going be on time not only because it's earlier but obviously the commercialization -- the authorization is also earlier. So I want to thank Jim Kelly, Dr. Robert Walker for joining us today for presentation on the Novavax. Hopefully, you got a taste and a bit of insight into what attractive investment opportunity this company is. And that if you haven't taken a look before or have perhaps looked in the past but decided to not take a position at that time, I think now is a time. The company is evolving in a positive direction and hopefully you got that insight from them. Thank you.

Jim Kelly

And thanks again, Vernon. Really enjoyed being here. And thank you all.
πŸ‘οΈ0
Monksdream Monksdream 4 weeks ago
NVAX under $15
πŸ‘οΈ0
mick mick 4 weeks ago
NVAX
Novavax Inc
11.60
-0.35 (-2.93%)
Volume: 2,767,404
Day Range: 11.43 - 12.12
Last Trade Time: 7:55:52 PM EDT
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 4 weeks ago
I'm surprised. I read about it on Stocktwits and verified for myself on X that the Japan post is gone. It might have been announced prematurely and Takeda wanted it removed. I've seen this happen a couple of times with other companies. We may learn more about this during the conferences Monday and Tuesday where Novavax is presenting. I feel confident this question will be raised. I'll be tuning in to both.

https://ir.novavax.com/press-releases/2024-09-04-Novavax-to-Participate-in-Upcoming-September-Conferences
πŸ‘οΈ0
justin77 justin77 4 weeks ago
They deleted the post about Japan approval on both X and LinkedIn! What is your thought about that?
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 4 weeks ago
Japan Approves Novavax Protein-based COVID-19 Vaccine

https://www.precisionvaccinations.com/2024/09/06/japan-approves-protein-based-covid-19-vaccine

Precision Vaccinations News
September 6, 2024

Novavax Inc. announced on X today that its updated 2024-2025 formula COVID-19 vaccine (NVX-CoV2705) has received Marketing Approval from Japan’s Ministry of Health, Labour and Welfare.

As of September 6, 2024, Novavax's vaccine is the only non-mRNA, protein-based COVID-19 vaccine available in the U.S. following the Food and Drug Administration (FDA) granting emergency use authorization.

John C. Jacobs, President, and Chief Executive Officer, Novavax, commented in a recent press release, "Our updated vaccine targets JN.1, the 'parent strain' of currently circulating variants, and has shown robust cross-reactivity against JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1."

Since August 2020, Novavax and Takeda Pharmaceutical Company Limited have partnered to develop, manufacture, and commercialize Novavax’s COVID-19 vaccines.

Before visiting Japan, the U.S. CDC recommends travelers speak with a healthcare provider one month before departure about their vaccination options.
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 4 weeks ago
NEWS: Novavax to Participate in Upcoming September Conferences

https://ir.novavax.com/press-releases/2024-09-04-Novavax-to-Participate-in-Upcoming-September-Conferences
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 1 month ago
Novavax appeared on the pitchers mound at Friday's Braves game. I wonder how many in the crowd may have looked up "Novavax" on their smartphone during the game and learned about the FDA approval of their non-mRNA Covid vaccine announced on Friday. Or perhaps looked at share price and took an interest to research the company over the weekend for a possible investment. Advertising dollars well spent, IMO.

πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 1 month ago
Moths and tree bark: How the Novavax vaccine works

This is an informative article from 2022 I came across while researching Matrix-M, the Novavax proprietary adjuvant. Worth a read.

https://www.nebraskamed.com/COVID/moths-and-tree-bark-how-the-novavax-vaccine-works

July 21, 2022

A fourth COVID-19 vaccine has been authorized in the United States. Called Novavax, it's a more traditional vaccine that uses moth cells and tree bark. Instead of an mRNA vaccine (Pfizer, Moderna) or a viral vector vaccine (Johnson & Johnson), Novavax is a subunit protein vaccine.

Infectious diseases expert Diana Florescu, MD, led the phase 3 clinical trial of the Novavax vaccine at the University of Nebraska Medical Center (UNMC). "Diversity in vaccine production helps increase the number of patients vaccinated," says Dr. Florescu. "Some might not accept mRNA vaccines, while others may be allergic to certain ingredients."

For example, some are allergic to polyethylene glycol (PEG), an ingredient in the mRNA (Pfizer and Moderna) vaccines. There's no polyethylene glycol (PEG) in Novavax.

How does the Novavax vaccine work?

The Novavax COVID-19 vaccine contains a protein (made using moth cells) plus an adjuvant (made from tree bark). An adjuvant is an ingredient added to boost a person's immune response, creating higher levels of antibodies.

The Novavax vaccine uses a telltale piece of the coronavirus: the notorious spike protein. All alone, the spike protein is harmless and can't cause COVID-19. When your immune system encounters the lonely spike protein, it produces antibodies against it. This gives you protection against future COVID-19 infection.

"Unlike mRNA vaccines, the spike protein is already premade in the Novavax vaccine. It's a shortcut," explains Dr. Florescu. "All the synthesis happens outside the body and we just give the end product: the spike protein."

Like other COVID-19 vaccines, Novavax does not cause COVID-19 infection. It can't get you sick. This vaccine doesn't contain either live or inactivated virus.

How did they get the spike protein?

The Novavax method uses moth cells to make spike proteins:

1. Researchers select the desired genes that create certain SARS-CoV-2 antigens (spike protein).
2. Researchers put the genes into a baculovirus, an insect virus.
3. The baculovirus infects moth cells and replicates inside them.
4. These moth cells create lots of spike proteins.
5. Researchers extract and purify the spike proteins.

"The Novavax vaccine has no genetic material, only proteins," says Dr. Florescu. "The vaccine technology is more traditional, and it's very similar to a protein-based influenza vaccine."

Influenza vaccines have also used this moth cell factory method.

What does the adjuvant (soapbark tree extract) do?

Adjuvants increase the immune response to a vaccine. In this vaccine, soapbark tree extract adjuvant makes achieving immunity possible with a smaller dose of the spike protein.

Matrix-M is the adjuvant used by Novavax. It is based on a saponin extracted from the soapbark tree (Quillaja saponaria). The soapbark extract encourages immune cells to activate, generating a more potent immune response.

Saponins are found naturally in various plant species like beans and green peas. They're used in agriculture, animal feeds, veterinary vaccines and human food. Saponins can boost immune responses to proteins. Using the Matrix-M adjuvant, a smaller dose of spike protein achieves the desired immune response.
πŸ‘οΈ0
JoeForkeyBolo JoeForkeyBolo 1 month ago
Updated Novavax Covid-19 vaccines could be available as early as next week

https://www.cnn.com/2024/08/30/health/novavax-covid-shot-fda/index.html

CNN
β€”
The US Food and Drug Administration on Friday authorized an updated version of the protein-based Novavax Covid-19 vaccine for use in people 12 and up. Doses could be available by the end of next week.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock